Application of machine learning to predict in-hospital mortality after transcatheter mitral valve repair

Transcatheter mitral valve repair offers a minimally invasive treatment option for patients at high risk for traditional open repair. We sought to develop dynamic machine-learning risk prediction models for in-hospital mortality after transcatheter mitral valve repair using a national cohort.

All adult hospitalization records involving transcatheter mitral valve repair were identified in the 2016-2020 Nationwide Readmissions Database. As a result of initial class imbalance, undersampling of the majority class and subsequent oversampling of the minority class using Synthetic Minority Oversampling TEchnique were employed in each cross-validation training fold. Machine-learning models were trained to predict patient mortality after transcatheter mitral valve repair and compared with traditional logistic regression. Shapley additive explanations plots were also developed to understand the relative impact of each feature used for training.

Among 2,450 patients included for analysis, the in-hospital mortality rate was 1.8%. Naïve Bayes and random forest models were the best at predicting transcatheter mitral valve repair postoperative mortality, with an area under the receiver operating characteristic curve of 0.83 ± 0.05 and 0.82 ± 0.04, respectively. Both models demonstrated superior ability to predict mortality relative to logistic regression (P < .001 for both). Medicare insurance coverage, comorbid liver disease, congestive heart failure, renal failure, and previous coronary artery bypass grafting were associated with greater predicted likelihood of in-hospital mortality, whereas elective surgery and private insurance coverage were linked with lower odds of mortality.

Machine-learning models significantly outperformed traditional regression methods in predicting in-hospital mortality after transcatheter mitral valve repair. Furthermore, we identified key patient factors and comorbidities linked with greater postoperative mortality. Future work and clinical validation are warranted to continue improving risk assessment in transcatheter mitral valve repair .